肿瘤突变负荷（TMB）与中国宣威地区表皮生长因子受体（EGFR）突变的非小细胞肺癌的预后相关。
TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China.
作者信息
Wang Han, Ma Junrui, Lu Jiagui, Wang Yang, Zhang Binli, Zhang Hushan, Peng Hao
机构信息
Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China.
School of Nursing, Yunnan University of Traditional Chinese Medicines, Kunming City, Yunnan Province, P.R. China.
出版信息
Biomark Med. 2024 Dec;18(24):1123-1133. doi: 10.1080/17520363.2024.2432306. Epub 2024 Dec 5.
AIMS
Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients.
MATERIALS AND METHODS
A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed.
RESULTS
The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors ( < 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC.
CONCLUSION
Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.
目的
研究宣威肺癌患者的预后特征及生物标志物。
材料与方法
对261例非小细胞肺癌患者的基因数据以及133例患者的预后数据进行回顾性分析。比较并分析宣威组和非宣威组预后与表皮生长因子受体（EGFR）突变之间的关系。
结果
主要在EGFR突变型肿瘤的宣威患者中观察到较好的无进展生存期（PFS）（<0.05）。对伴随突变和肿瘤突变负荷（TMB）水平的进一步分析显示，高TMB与EGFR突变的宣威非小细胞肺癌患者的良好预后相关。
结论
宣威肺癌在预后和肿瘤突变负荷方面与非宣威患者不同，应进一步开展研究。
Zotero 插件